Muscarinic M1 agonist as an inhibitor of beta-amyloid (ABeta40 and ABeta42)-synthesis

摘要

A method of lowering the levels of Abeta40, Abeta42, and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine or a physiologically acceptable acid addition salt thereof and methods of treating or preventing diseases associated with the formation of diffuse and senile plaques or Abeta40-, Abeta42- and tau-containing plaques.